Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250022/S006

Volt PFA System

ABBOTT MEDICAL · Decision date Jul 10, 2026

FDA DECISIONP250022/S006

What did the FDA approve?

FDA records P250022/S006 as a supplement to PMA P250022, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 10, 2026.

FDA approval order statement

approval for additional manufacturing activities at Minnetonka, Minnesota
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Jul 10, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P250022/S006
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Jul 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P250022. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250022/S001 · Related supplement

    Volt PFA Catheter Sensor Enabled

  2. P250022/S004 · Related supplement

    Volt PFA Catheter, Sensor Enabled

  3. P250022/S006 received

    Application receipt date recorded by FDA.

  4. P250022/S007 · Related supplement

    VOLT PFA CATHETER, SENSOR ENABLED

  5. P250022/S006 · FDA decision

    Normal 180 Day Track No User Fee

  6. P250022/S005 · Related supplement

    Current PFA Generator TactiFlex Duo

  7. P250022/S008 · Related supplement

    Volt PFA Catheter, Sensor Enabled

  8. P250022/S009 · Related supplement

    Volt PFA Catheter, Sensor Enabled

  9. P250022/S012 · Related supplement

    VOLT PFA CATHETER, SENSOR ENABLED

Timeline entries are records held by MedtechLedger for P250022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250022

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalDec 19, 2025FDA
ABBOTT MEDICALPMA supplementMar 23, 2026FDA
ABBOTT MEDICALPMA supplementApr 13, 2026FDA
Volt PFA SystemP250022/S003
ABBOTT MEDICALPMA supplementApr 16, 2026FDA
ABBOTT MEDICALPMA supplementJun 22, 2026FDA
ABBOTT MEDICALPMA supplementJul 23, 2026FDA
ABBOTT MEDICALPMA supplementAug 11, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
5050 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records